- Pfizer's (PFE) Bivalent rLP2086 treatment has received a breakthrough designation from the FDA for preventing Meningococcal B Disease in sufferers aged 10-25.
- Pfizer is conducting Phase II and III trials for rLP2086 in studies that involve over 20,000 participants, of which 14,000 will receive the vaccine.
- Meningococcal disease is caused by a bacterium called Neisseria meningitidis and can lead to meningitis and widespread blood infection (sepsis), as well as death or long-term disabilities such as brain damage and hearing loss.
- Of the five main meningococcal serogroups, serogroup B is the only one for which there is no FDA approved broadly-protective vaccine. (PR)
From other sites
Video at CNBC.com (Mon, 5:45PM)
at CNBC.com (Jun 1, 2015)
at CNBC.com (May 28, 2015)
at CNBC.com (Apr 10, 2015)
at CNBC.com (Mar 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs